Limited Availability — 10 seats remain
LiveWhat's going to stall your commercialization?
Find out before your investors, partners, or buyers do.
The CLIF Analysis is a fast, external diagnostic that pressure-tests your commercial story before investors, partners, or health systems do it for you.
For a limited cohort of ten companies, we're opening a deeper version of that process — two passes through the analysis, with refinement between — at a reduced rate.
Most teams don't pressure-test their commercial story ahead of time.
They only find out where it breaks when it actually matters.
The CLIF Analysis surfaces those gaps earlier—
before you have to answer for them.
What you get
CLIF Analysis — initial pass
A structured external read on your commercial story based on your materials. Surfaces where the logic holds — and where it doesn't.
Direct input into the framework
Your feedback helps refine how the diagnostic interprets real-world commercial scenarios across medtech.
CLIF Analysis — refined pass
A second run incorporating learnings from across the cohort. Sharper, more calibrated, and more aligned to how buyers actually evaluate.
$6,500 — half the standard rate
Offered at half the standard $13,000 engagement rate in exchange for participation and structured feedback. No obligation beyond the engagement.
This is not a beta.
It's a structured diagnostic engagement designed to sharpen a tool already in use — while giving you a clearer view of where your commercial story may stall.
What we ask in return
This is a structured engagement with a feedback component. In exchange for the reduced rate, cohort participants agree to:
- Provide structured feedback after the first report — what landed, what missed, what was unclear
- Complete a short final feedback form after the second report
- Submit an attributed testimonial at the end of the engagement. This is a condition of the Pioneer Cohort pricing. We'll ask for your honest take, not a polished endorsement.
There is no ongoing commitment. No retainer. No follow-on obligation.
This is a fit if you are:
- A medtech or medical device company at a commercial inflection point
- Preparing to raise, launch, partner, or diagnose stalled traction
- Able to provide honest feedback, not just polite feedback
This is not a fit if you are:
- Seeking validation rather than critique
- Not yet ready to act on what you find
- Unwilling to provide an attributed testimonial
Ten seats. First come, first served.
Your data is protected
Each participant's materials, findings, and report are kept strictly confidential. Nothing you share is visible to other cohort members. We will never reference your company name, specific findings, or proprietary information in our marketing without your explicit permission.
What we retain the right to use are aggregate learnings and anonymized patterns observed across the cohort. We will also use your attributed testimonial at the end of the engagement — this is a condition of the Pioneer Cohort pricing. Your company name can be withheld from broader marketing materials on request, but the testimonial must be attributable to a named individual. We'll work with you on the language.
If you're not comfortable with any of this,
we'll tell you plainly: this cohort may not be the right fit.
How it works
Step 01
Apply and submit your materials
Complete the intake form, submit your public-facing materials — pitch deck, website, one-pager, data summaries — and pay $6,500 via Stripe. Once confirmed, you're in.
Step 02
Receive your CLIF v1 report
We run the analysis and deliver your report within approximately one week. Take up to five days to review it.
Step 03
Share structured feedback
Complete a short feedback form — what rang true, what felt off, what was missing. About ten minutes.
Step 04
Receive your CLIF v2 report
We integrate cohort feedback, refine the framework, and run the analysis again. Your updated report follows shortly after.
Step 05
Close out
Final feedback form, then a short testimonial request. You're done. We're grateful.
Research Brief
Understand the risk first
Why do medtech commercialization efforts stall? We put together a short, evidence-based breakdown of where companies actually stall — and why most teams don't see it coming until it's already costly.
Read the white paperFrequently asked questions
The CLIF Analysis (Commercial Launch & Impact Framework) is an existing RŌG Health diagnostic — not a new or experimental product. It's a fast, external assessment that evaluates your commercial story based on your public-facing materials. It surfaces gaps in clarity, buyer logic, differentiation, and execution readiness, and tells you where the story holds up and where it breaks. The Pioneer Cohort is not a test of whether the CLIF works — it's a structured engagement to refine and sharpen a framework that's already in use. For companies at higher-stakes inflection points, we may recommend the full Commercial Readiness Diagnostic (CRD) instead.
Because you're contributing something valuable: structured feedback and a testimonial that helps us improve the product and build credibility. That has real worth to us, and we're pricing accordingly.
We work exclusively from public-facing materials — the kind of content you'd share with a potential investor, partner, or customer. This typically includes a pitch deck, website, product one-pager, pilot or data summaries, ROI models, or any other external-facing assets that represent your current commercial story. You don't need everything on that list, and nothing needs to be polished or complete. Submit what you have. Internal strategy documents, clinical files, or confidential data are neither needed nor appropriate to share.
No. Your submissions and report are completely confidential. Other participants will never see your materials, your findings, or your company name.
Yes — this is a condition of the Pioneer Cohort pricing. We'll ask for your honest take, not a polished endorsement. If you're not comfortable providing an attributable testimonial at the end of the engagement, this isn't the right program.
You can request that your company name not be used in broader marketing materials. However, the testimonial must be attributable to a named individual to carry credibility. We'll work with you on the language.
Nothing, unless you want it to. The CRD is a natural next step for companies that discover deeper issues through the CLIF process, but there is no obligation and no pitch. If the diagnostic surfaces something that warrants a larger engagement, we'll tell you plainly and let you decide.
Ten. When they're filled, the cohort closes. There is no waitlist for this round.
Ten seats. Early access. Reduced rate.
If you're heading into a moment where your commercial story will be tested, this is when clarity matters most.
By completing the intake form and submitting payment, you agree to provide structured feedback and an attributed testimonial as outlined above. Your materials and findings will not be shared with other cohort participants. RŌG Health retains the right to use anonymized aggregate learnings and attributed testimonials in marketing materials. Company-specific findings will never be referenced without explicit written permission.